JP2011526482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526482A5 JP2011526482A5 JP2011515374A JP2011515374A JP2011526482A5 JP 2011526482 A5 JP2011526482 A5 JP 2011526482A5 JP 2011515374 A JP2011515374 A JP 2011515374A JP 2011515374 A JP2011515374 A JP 2011515374A JP 2011526482 A5 JP2011526482 A5 JP 2011526482A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomer
- mtgpat1
- oligomer according
- nucleotide
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 13
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 208000004930 Fatty Liver Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7794208P | 2008-07-03 | 2008-07-03 | |
| US61/077,942 | 2008-07-03 | ||
| EP08104623.7 | 2008-07-03 | ||
| EP08104623 | 2008-07-03 | ||
| PCT/EP2009/057907 WO2010000656A1 (en) | 2008-07-03 | 2009-06-24 | Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526482A JP2011526482A (ja) | 2011-10-13 |
| JP2011526482A5 true JP2011526482A5 (OSRAM) | 2012-05-24 |
Family
ID=41066150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515374A Withdrawn JP2011526482A (ja) | 2008-07-03 | 2009-06-24 | ミトコンドリアグリセロール−３−リン酸アシルトランスフェラーゼ１（ｍｔｇｐａｔ１）の発現を阻害するためのｒｎａアンタゴニスト化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120004276A1 (OSRAM) |
| EP (1) | EP2310504A1 (OSRAM) |
| JP (1) | JP2011526482A (OSRAM) |
| KR (1) | KR20110031368A (OSRAM) |
| CN (1) | CN102076854A (OSRAM) |
| AU (1) | AU2009265836A1 (OSRAM) |
| BR (1) | BRPI0915837A2 (OSRAM) |
| CA (1) | CA2729897A1 (OSRAM) |
| EA (1) | EA201170131A1 (OSRAM) |
| MX (1) | MX2010013552A (OSRAM) |
| WO (1) | WO2010000656A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101914309B1 (ko) * | 2010-06-23 | 2018-11-02 | 큐알엔에이, 인크. | 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료 |
| EP2638163B1 (en) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US20140050728A1 (en) * | 2011-01-28 | 2014-02-20 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications |
| CN104583398A (zh) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节基因表达的组合物和方法 |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| MX2015009056A (es) | 2013-01-30 | 2015-10-05 | Hoffmann La Roche | Conjugados de oligonucleotidos de acido nucleico bloqueado y carbohidratos. |
| CN105039513B (zh) * | 2015-05-29 | 2018-12-28 | 广州市第一人民医院 | 用于非酒精性脂肪肝相关目的基因多态性检测方法及其引物，以及试剂盒 |
| CN104997768B (zh) * | 2015-07-23 | 2017-11-17 | 上海市第六人民医院 | 鱼藤酮在制备降血糖药物中的应用 |
| CN116075592A (zh) * | 2020-06-09 | 2023-05-05 | 阿尔尼拉姆医药品有限公司 | 用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法 |
| GB202015056D0 (en) * | 2020-09-23 | 2020-11-04 | Cambridge Entpr Ltd | Biomarkers |
| US12215322B2 (en) | 2021-02-27 | 2025-02-04 | Regeneron Pharmaceuticals, Inc. | Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors |
| EP4419682A2 (en) * | 2021-10-22 | 2024-08-28 | Amgen Inc. | Rnai constructs for inhibiting gpam expression and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002364900A1 (en) * | 2001-11-30 | 2003-06-17 | Bristol-Myers Squibb Company | Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof |
| US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
-
2009
- 2009-06-24 US US13/000,974 patent/US20120004276A1/en not_active Abandoned
- 2009-06-24 KR KR1020117002768A patent/KR20110031368A/ko not_active Withdrawn
- 2009-06-24 CA CA2729897A patent/CA2729897A1/en not_active Abandoned
- 2009-06-24 EA EA201170131A patent/EA201170131A1/ru unknown
- 2009-06-24 EP EP20090772356 patent/EP2310504A1/en not_active Withdrawn
- 2009-06-24 WO PCT/EP2009/057907 patent/WO2010000656A1/en not_active Ceased
- 2009-06-24 AU AU2009265836A patent/AU2009265836A1/en not_active Abandoned
- 2009-06-24 JP JP2011515374A patent/JP2011526482A/ja not_active Withdrawn
- 2009-06-24 BR BRPI0915837A patent/BRPI0915837A2/pt not_active Application Discontinuation
- 2009-06-24 MX MX2010013552A patent/MX2010013552A/es not_active Application Discontinuation
- 2009-06-24 CN CN200980124993.0A patent/CN102076854A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526482A5 (OSRAM) | ||
| JP2011504362A5 (OSRAM) | ||
| US20230210887A1 (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection | |
| JP2015511821A5 (OSRAM) | ||
| JP2010524486A5 (OSRAM) | ||
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| US12303525B2 (en) | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection | |
| US11732262B2 (en) | Use of FUBP1 inhibitors for treating hepatitis B virus infection | |
| JP2012050438A5 (OSRAM) | ||
| JP2012029693A5 (OSRAM) | ||
| JP2018529732A5 (OSRAM) | ||
| JP2009508527A5 (OSRAM) | ||
| JP2014509512A (ja) | オリゴマーの増強された体内分布 | |
| TW201249988A (en) | Modulation of hepatitis B virus (HBV) expression | |
| JP2014504857A5 (OSRAM) | ||
| TW202113082A (zh) | 靶向atxn3的反義寡核苷酸 | |
| JP2016520310A5 (OSRAM) | ||
| JP7616987B2 (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2013537404A5 (OSRAM) | ||
| JP2011519365A5 (OSRAM) | ||
| JP2006514546A5 (OSRAM) | ||
| US11898145B2 (en) | Enhanced oligonucleotides for inhibiting RTEL1 expression | |
| CN117280030A (zh) | 用于治疗缺氧和缺血相关病症的药剂、组合物和方法 | |
| WO2021020412A1 (ja) | Ｍｕｒｆ１を標的とする核酸医薬 | |
| WO2023111210A1 (en) | Combination of oligonucleotides for modulating rtel1 and fubp1 |